Also, our results revealed that coadministration of As2O3 and EGFR TKIs sensitized drug effects of lung cancer cells regardless of EGFR mutation status, which may expand the beneficial application of EGFR TKIs in lung cancer patients with amplified wild-type EGFR. The gene discussed is EGFR; the disease is lung carcinoma.